Literature DB >> 11804689

Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung.

Tatsuo Nakagawa1, Fumihiro Tanaka, Yosuke Otake, Kazuhiro Yanagihara, Ryo Miyahara, Katsunari Matsuoka, Tetsuya Takata, Tomoko Yamada, Masakazu Fukushima, Hiromi Wada.   

Abstract

We investigated thymidylate synthase (TS) expression in tumor tissues and examined the relationship between TS expression and post-operative survival in patients with p-stage I adenocarcinoma of the lung. A total of 104 patients, who underwent complete resection for p-stage I adenocarcinoma of the lung, were retrospectively reviewed. TS expression in tumor tissues was evaluated by immunohistochemical staining using rhTS polyclonal antibody. The intensity of immunohistochemical staining was classified into four categories using a visual grading system from 0 to 3. The percentage of each grade of TS staining was 9.6% for Grade 0, 18.3% for Grade 1, 35.6% for Grade 2 and 36.5% for Grade 3. Five-year survival rates of patients with Grade 0 to Grade 3 were 90.0, 83.9, 70.3 and 73.7%, respectively with no significant difference among all groups (P=0.236). When divided into two groups, according to the intensity of the grade, 5-year survival rates of TS low expression group (Grade 0 and Grade 1) and TS high expression group (Grade 2 and Grade 3) were 86.1 and 72.0%, respectively, with a significant difference (P=0.048). In conclusion, high level of TS expression was associated with poor prognosis. Immunohistochemical evaluation of TS expression may be useful to predict survival after complete resection in p-stage I adenocarcinoma of the lung.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11804689     DOI: 10.1016/s0169-5002(01)00407-x

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  11 in total

1.  Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer.

Authors:  Murry W Wynes; Krzysztof Konopa; Shalini Singh; Bernadette Reyna-Asuncion; James Ranger-Moore; Adam Sternau; Daniel C Christoph; Rafal Dziadziuszko; Jacek Jassem; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2012-06       Impact factor: 15.609

Review 2.  Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Authors:  Bartomeu Massuti; Jose Miguel Sanchez; Florentino Hernando-Trancho; Niki Karachaliou; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2013-06

3.  Variation in the expression levels of predictive chemotherapy biomarkers in histological subtypes of lung adenocarcinoma: an immunohistochemical study of tissue samples.

Authors:  Yuichi Fujimoto; Shinsaku Togo; Miniwan Tulafu; Kazue Shimizu; Takuo Hayashi; Toshimasa Uekusa; Yuichirou Honma; Yukiko Namba; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki; Kazuhisa Takahashi
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.

Authors:  Sehhoon Park; Bhumsuk Keam; Se Hyun Kim; Ki Hwan Kim; Yu Jung Kim; Jin-Soo Kim; Tae Min Kim; Se-Hoon Lee; Dong-Wan Kim; Jong Seok Lee; Dae Seog Heo
Journal:  Cancer Res Treat       Date:  2015-02-16       Impact factor: 4.679

5.  Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients.

Authors:  Yan Huang; Xiuhua Guo; Hongyang Wang; Tienian Zhu
Journal:  Oncol Lett       Date:  2014-11-03       Impact factor: 2.967

6.  Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients.

Authors:  Hong-Yun Zhao; Guo-Wei Ma; Ben-Yan Zou; Mei Li; Su-Xia Lin; Li-Ping Zhao; Ying Guo; Yan Huang; Ying Tian; Dan Xie; Li Zhang
Journal:  Onco Targets Ther       Date:  2014-07-16       Impact factor: 4.147

7.  Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Authors:  Fabian Dominik Mairinger; Claudia Vollbrecht; Elena Flom; Daniel Christian Christoph; Kurt-Werner Schmid; Jens Kollmeier; Helmut Hans Popper; Thomas Mairinger; Robert Fred Henry Walter
Journal:  Oncotarget       Date:  2017-06-06

8.  Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.

Authors:  Francesco Grossi; Maria Giovanna Dal Bello; Sandra Salvi; Roberto Puzone; Ulrich Pfeffer; Vincenzo Fontana; Angela Alama; Erika Rijavec; Giulia Barletta; Carlo Genova; Claudio Sini; Giovanni Battista Ratto; Mario Taviani; Mauro Truini; Domenico Franco Merlo
Journal:  Dis Markers       Date:  2015-11-17       Impact factor: 3.434

9.  Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis.

Authors:  Ting Wang; Chang Chuan Pan; Jing Rui Yu; Yu Long; Xiao Hong Cai; Xu De Yin; Li Qiong Hao; Li Li Luo
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

Review 10.  The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis.

Authors:  Lei Wang; Rui Wang; Yunjian Pan; Yihua Sun; Jie Zhang; Haiquan Chen
Journal:  BMC Cancer       Date:  2014-03-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.